Flecainide Acetate
Flecainide belongs to a group of medicines that counteract heart rhythm disorders (known as anti-arrhythmic medicines). The medicine inhibits the conduction of impulses in the heart and prolongs the time during which the heart is at rest, causing the heart to pump blood properly again.
Flecainide Acetate Holsten is used:
Before starting to take Flecainide Acetate Holsten, discuss it with your doctor or pharmacist.
An increased or decreased potassium level in the blood may affect the action of this medicine. Diuretics, laxatives, and adrenal cortex hormones (corticosteroids) may decrease the potassium level. In this case, your doctor should check the potassium level in your blood.
Flecainide is not approved for use in children under 12 years of age.
Tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as about the medicines you plan to take.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
This medicine can be used during pregnancy only if the benefits outweigh the risks, as flecainide passes through the placenta. In the case of flecainide use during pregnancy, the mother's flecainide concentration should be monitored. Consult your doctor as soon as you think you may be pregnant or plan to have a child.
Flecainide passes into breast milk. This medicine can be used during breastfeeding only if the benefits outweigh the risks.
If you experience side effects such as dizziness, double vision, or blurred vision, or if you feel dizzy, it may prolong your reaction time.
This may be dangerous in situations that require concentration and attention, such as when driving or operating heavy machinery.
If you are unsure whether this medicine affects your ability to drive, consult your doctor.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you.
If you are unsure, consult your doctor or pharmacist.
Your doctor will prescribe the individual dose.
Treatment with this medicine usually starts under the supervision of a doctor (if necessary, in a hospital setting).
While taking this medicine, follow your doctor's instructions carefully.
Swallow the tablets with a sufficient amount of liquid (e.g., water).
Usually, the daily dose should be divided throughout the day.
The general dosing schedule is for guidance only and is as follows:
For patients with ventricular arrhythmias whose cause is located in the atria, the recommended dose is 50 mg twice a day.
If necessary, your doctor may increase the dose to a maximum of 300 mg per day.
For patients with ventricular arrhythmias, the recommended dose is 100 mg twice a day.
The maximum daily dose is 400 mg. This dose is usually used for patients of large stature or for patients who require rapid control of arrhythmia.
After 3-5 days, your doctor will usually gradually reduce the dose to the smallest effective dose.
If necessary, your doctor may reduce the dose during long-term treatment.
For elderly patients
In elderly patients, the elimination rate may be lower.
Your doctor will take this into account.
The dose for elderly patients should not exceed 300 mg per day (or 150 mg twice a day).
Patients with renal impairment
In these patients, the maximum initial dose is 100 mg per day (or 50 mg twice a day), and your doctor should regularly monitor the flecainide concentration.
Patients with hepatic impairment
Your doctor may prescribe a lower dose.
Patients with a permanently implanted pacemaker
The daily dose should not exceed 200 mg per day (or 100 mg twice a day).
Patients treated with cimetidine (a medicine used to treat stomach and intestinal disorders) or amiodarone (a medicine used to treat arrhythmias)
Your doctor will regularly monitor your condition and may prescribe a lower dose for some patients.
During treatment, your doctor will regularly monitor the flecainide concentration in your blood and perform an electrocardiogram (ECG) of your heart.
Every month, a basic ECG will be performed, and every three months, a more detailed ECG will be performed.
An ECG will be performed more frequently in patients who receive a dose lower than the usual recommended dose.
Your doctor may adjust the dose at intervals of 6-8 days.
In such cases, an ECG should be performed in these patients in the 2nd and 3rd week after starting treatment.
Use in children
These tablets should not be used in children under 12 years of age.
Flecainide Acetate Holsten, 100 mg, tablets
The tablet can be divided into equal doses.
In case of accidental ingestion of too many tablets, go to the nearest hospital emergency department immediately.
Take the missed dose as soon as possible, unless it is time for the next dose.
In this case, the patient may not take an additional dose, but must continue taking the medicine according to the dosing schedule.
It is important to take the tablets according to the dosing schedule.
If you are unsure, consult your doctor.
Do not take a double dose to make up for a missed dose.
In case of sudden discontinuation of this medicine, no withdrawal symptoms occur.
The heart action will no longer be controlled.
Therefore, never stop taking this medicine without consulting your doctor.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
As with other anti-arrhythmic medicines, flecainide may cause arrhythmia.
Existing arrhythmia may worsen or new arrhythmia may occur.
The pro-arrhythmic effect occurs mainly in patients with heart defects and/or significant reduction of heart function.
The most common side effects from the heart are decreased or increased heart rate (bradycardia, tachycardia), heart palpitations, cardiac arrest, heart failure, chest pain, heart attack, and decreased blood pressure (hypotension).
Other side effects may occur, including:
Very common(may affect more than 1 in 10 people):
dizziness, feeling of emptiness in the head, vision problems, such as double vision and blurred vision, and difficulty concentrating.
Common(may affect up to 1 in 10 people):
the occurrence of a more severe type of arrhythmia or an increase in the frequency or severity of existing arrhythmias (pro-arrhythmia), shortness of breath, weakness, fatigue, fever, and fluid retention (edema), discomfort.
Uncommon(may affect up to 1 in 100 people):
nausea, vomiting, constipation, abdominal pain, loss of appetite, diarrhea, indigestion, bloating, decreased red blood cell, white blood cell, and platelet count, increased heart rate in patients with atrial fibrillation, skin allergic reactions such as rash, hair loss, dry mouth, taste disorders.
Rare(may affect up to 1 in 1,000 people):
pneumonia, tingling sensation, coordination problems, difficulty controlling movements (tics), decreased sensitivity, increased sweating, fainting, tinnitus, tremors, vertigo, flushing, drowsiness, severe depression, anxiety, insomnia, headache, nerve disorders, e.g., of the upper and lower limbs, seizures, confusion, hallucinations, memory loss, hives, increased liver enzyme activity with or without jaundice.
Very rare(may affect up to 1 in 10,000 people):
increased levels of certain antibodies, deposition of deposits in the cornea (small, cloudy spots on the eyeball) with increased sensitivity to light.
Not known(frequency cannot be estimated from the available data):
certain changes in the ECG (prolongation of the PR and QRS intervals), increased threshold in patients with a pacemaker or electrodes for temporary stimulation, slowing of conduction between the atria and ventricles (second- or third-degree atrioventricular block), cardiac arrest, slowing or acceleration of heart rate, decreased ability of the heart to pump enough blood to the body, chest pain, low blood pressure, heart attack, feeling of heart palpitations, interruption of normal heart action (sinoatrial block), ventricular fibrillation, occurrence of a certain existing heart disease (Brugada syndrome) that did not show symptoms before starting treatment with flecainide, pulmonary fibrosis or lung disease (pulmonary fibrosis and interstitial lung disease), liver disease, joint pain, and muscle pain.
If you experience any side effects, including those not listed in this package leaflet, please inform your doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181 C, 02-222 Warsaw
Tel.: +48 22 49 21 301, Fax: + 48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after EXP.
The expiry date refers to the last day of the month.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste.
Ask your pharmacist how to dispose of medicines that are no longer needed.
This will help protect the environment.
Flecainide Acetate Holsten, 50 mg, tablets
White or almost white, round, biconvex tablets with a diameter of 7 mm.
Flecainide Acetate Holsten, 100 mg, tablets
White or almost white, round, biconvex tablets with a diameter of 9 mm and a score line on one side.
The tablet can be divided into equal doses.
Flecainide Acetate Holsten tablets are packaged in PVC/PVDC/Aluminum blisters containing 20, 30, 50, or 100 tablets, in a cardboard box.
Holsten Pharma GmbH
Hahnstraße 31-35
60528 Frankfurt am Main
Germany
Alkaloid-INT d.o.o.
Šlandrova ulica 4
1231 Ljubljana-Črnuče
Slovenia
Netherlands
Flecainide Alkaloid-INT 50 mg tablets
Flecainide Alkaloid-INT 100 mg tablets
Bulgaria
Felkarid 50 mg tablets
Felkarid 100 mg tablets
Germany
Flecainid AAA-Pharma 50 mg tablets
Flecainid AAA-Pharma 100 mg tablets
Croatia
Felkarid 50 mg tablets
Felkarid 100 mg tablets
Poland
Flecainide Acetate Holsten
Slovenia
Felkarid 50 mg tablets
Felkarid 100 mg tablets
Date of last revision of the package leaflet:04/2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.